New hope for kids with tough leukemia: experimental combo tested
NCT ID NCT04915612
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a combination of three chemotherapy drugs (CPX-351 and gemtuzumab ozogamicin) in children whose acute myeloid leukemia (AML) had come back or didn't respond to standard treatment. The main goals were to find the best dose and check for side effects. Only one patient took part, so results are very limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can a liposomal chemo combo outsmart tough leukemias?
- Can a Platelet-Boosting drug speed recovery for older leukemia patients?
- Radioactive antibody hones in on cancer cells to boost transplant success
- Could a targeted drug keep AML in check?
- New drug aims to wake up immune system against Hard-to-Treat leukemia